

# Characterization of *Pseudomonas aeruginosa* Strains Isolated from Burned Patients Hospitalized in a Major Burn Center in Tehran, Iran

Reza Ranjbar<sup>1</sup>, Parviz Owlia<sup>2</sup>, Horie Sadari<sup>2</sup>, Sadegh Mansouri<sup>2</sup>,  
Nematollah Jonaidi-Jafari<sup>3</sup>, Morteza Izadi<sup>3</sup>, Shohreh Farshad<sup>4</sup>, and Mohammad Arjomandzadegan<sup>5</sup>

<sup>1</sup> Molecular Biology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

<sup>2</sup> Department of Microbiology, Faculty of Medicine, Shahed University of Medical Sciences, Tehran, Iran

<sup>3</sup> Health Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

<sup>4</sup> Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

<sup>5</sup> Tuberculosis and Pediatric Infectious Diseases Research Center, Arak University of Medical Sciences, Arak, Iran

Received: 17 Jan. 2011; Received in revised form: 21 May 2011; Accepted: 29 Jul. 2011

**Abstract-** *Pseudomonas aeruginosa* is an important life-threatening nosocomial pathogen and plays a prominent role in serious infections in burned patients. The current study was undertaken to characterize *P. aeruginosa* strains isolated from burned patients in Tehran, Iran. The study was conducted in a major burn center in Tehran, Iran in 2007. A total of seventy specimens obtained from different clinical origin with positive culture results for *P. aeruginosa* were included in the study. Antimicrobial susceptibility test was performed according to the standard CLSI guideline. The relationship between the strains was also determined using antimicrobial drug resistance pattern analysis and plasmid profiling. All strains were multi drug resistant. The percentage of resistance to tested antibiotics was: imipenem 97.5%, amikacin 90%, piperacillin 87.5%, ceftizoxime 72.7%, gentamicin 67.5%, ciprofloxacin 65%, ceftriaxone 60%, and ceftazidime 57.5%. Thirteen resistant phenotypes were recognized, R3 (TET, IPM, AMK, CIP, PIP, GM, CAZ, CRO, CT) was the predominant resistance pattern seen in 27.5% of isolates. Results obtained from E-test showed that 100% of *P. aeruginosa* strains were resistant to ceftoxitin, 97% to cefotetan, 93% to ticarcillin, 89% to ticarcillin/clav, 76% to gentamicin and imipenem, 63% to piperacillin, 49% to tetracycline, and 20% to meropenem. Nine different plasmid profiles were observed among the strains. The current study showed an increase rate of resistance for some antibiotics tested among *P. aeruginosa* strains isolated from burned patients in Tehran. A combination of antibiotic susceptibility testing and profile plasmid analysis, which are relatively cheap and available methods, showed to be useful to characterize the clinical strains of *P. aeruginosa* isolated from burned patients in Iran.

© 2011 Tehran University of Medical Sciences. All rights reserved.

*Acta Medica Iranica*, 2011; 49(10): 675-679.

**Keywords:** *Pseudomonas aeruginosa*; Antimicrobial susceptibility; Plasmid profiles

## Introduction

Burn injury as one of the most common and devastating forms of trauma, is a major public health problem worldwide (1). The risk of infections in burns is well known. Available current techniques of burn wound care have significantly decreased the incidence of infections in patients with burn wounds (2), however severely burned patients may still develop life-threatening infections. *Pseudomonas aeruginosa* as an important life-threatening nosocomial pathogen plays a prominent role in serious infections in burn patients. The condition

for patients infected by this bacterium is particularly problematic since the organism is intrinsically resistant to many drug classes and is able to acquire resistance to all effective antimicrobial drugs (3). *P. aeruginosa* isolates are resistant to many commonly used antibiotics (4). Some studies carried out in Iran have also indicated that infections caused by multi drug resistant (MDR) *P. aeruginosa* are widespread among Iranian hospitals (5-6). Many simple molecular methods such as plasmid profile have been used for epidemiological investigation of infections caused by multi drug resistant *P. aeruginosa* (5-6).

**Corresponding Author:** Parviz Owlia

Department of Microbiology, Faculty of Medicine, Shahed University of Medical Sciences, Tehran, Iran  
Tel: +98 21 66582540, Fax: +98 21 66582542, E-mail: owlia@shahed.ac.ir

## Characterization of *Pseudomonas aeruginosa* strains

The current research was undertaken to assess the new situation of antimicrobial resistance and to study the plasmid profiles of *P. aeruginosa* strains isolated from burn patients hospitalized in a main burn center in Iran in 2007.

### Material and Methods

The study was conducted from March through November 2007 at Motahari Hospital, a major center for admission of burned patients in Tehran, Iran. A total of 70 specimens obtained from different clinical origins with positive culture results for *P. aeruginosa* were included in the study. Cultures of the burn wounds were performed using swabs on the admission and all clinically indicated cultures such as blood, tissue, and urine were also evaluated. They were plated primarily onto blood agar and incubated at 37 °C for 24–48 h. Suspect isolates were presumptively identified by colony morphology, growth at 44 °C, pigment formation, positive oxidase test, glucose fermentation, hydrolysis of arginine, nitrate production and growth on acetamide agar (7,8).

Antimicrobial susceptibility test was performed according to the standard CLSI guideline (9) by disk diffusion using 9 antibiotic disks (MAST Group LTD, Merseyside, UK): ceftriaxone (CRO, 30 µg); ceftizoxime (CT, 30 µg); ceftazidime (CAZ, 30 µg); amikacin (AMK, 30 µg); tetracycline (TET, 30 µg); ciprofloxacin (CIP, 5 µg); gentamicin (GM, 10 µg); piperacillin (PIP, 100 µg) and imipenem (IPM, 10 µg). Standard strain of *P. aeruginosa* ATCC 27853 was used as a quality control strain. E-test method was used for determination of MIC using ceftoxitin, cefotetan, ticarcillin, ticarcillin/clav, gentamicin, imipenem, piperacillin, tetracycline, and meropenem strips.


Plasmids were extracted as previously described (10–12). Extracted plasmids were then separated on a 0.8% agarose gel in tris-borate-EDTA buffer (TBE×1) (pH

8.2) by electrophoresis at 45V for 4–5 h, stained with ethidium bromide and visualized under UV illumination. The strains were grouped depending on the size and number of the plasmid DNA bands.


### Results

The distribution of *P. aeruginosa* among the clinical samples was as follows: burn wound swab 72.3%, tissue biopsy 15.4%, urine 7.7%, sputum 3%, and blood 1.5%.

All isolates were resistant to tetracycline. The percentage of resistance to other antibiotics for these isolates was as follows: imipenem 97.5%, amikacin 90%, piperacillin 87.5%, ceftizoxime 72.7%, gentamicin 67.5%, ciprofloxacin 65%, ceftriaxone 60%, and ceftazidime 57.5%. The predominant resistance pattern, R3 (TET, IPM, AMK, CIP, PIP, GM, CAZ, CRO, CT) was observed in 27.5% of isolates. The least resistance patterns were exhibited by 2.5% of isolates showing resistance corresponding to patterns R2, R5, R8, R9 and R13 (Table 1).



**Figure 1.** Plasmid profiles of *P. aeruginosa* isolates. Lanes P1-P9 are representative plasmid profiles of the strains. Lane M is DNA marker (molecular ladder).



**Figure 2.** A UPGMA dendrogram showing distribution of plasmid profiles of *Pseudomonas aeruginosa* isolates. Lanes P1-P9 are representative plasmid profiles of the strains. The arrow indicates the DNA band evident in most isolates. UPGMA=Un-weighted pair group method with arithmetic averages.

**Table 1.** Plasmid profiles and antimicrobial resistance patterns of *P. aeruginosa*

Plasmid pattern	Size (kbp) of plasmids	% of isolates	Resistance Pattern (%)	Resistance phenotype*
P1	1.4	12.5	R1 (7.5)	TET, IPM, AMK, PIP, CRO
			R2 (2.5)	TET, IPM, AMK, PIP, GM, CAZ, CT
			R3 (2.5)	TET, IPM, AMK, CIP, PIP, GM, CAZ, CRO, CT
P2	1.3, 1.7	30	R4 (2.5)	TET, IPM, AMK, CIP, PIP, GM, CT
			R5 (2.5)	TET, IPM, AMK, CIP, PIP, CT
			R6 (2.5)	TET, IPM, AMK, CIP, PIP, GM, CAZ, CT
			R1 (2.5)	TET, IPM, AMK, PIP, CRO
			R7 (2.5)	TET, IPM, AMK, CIP, PIP, GM, CAZ
			R9 (2.5)	TET, IPM, AMK, PIP, GM, CAZ, CRO
			R3 (15)	TET, IPM, AMK, CIP, PIP, GM, CAZ, CRO, CT
P3	1.4, 1.9	22.5	R10 (5)	TET, IPM, AMK, CIP, PIP, GM, CAZ, CRO
			R11 (10)	TET, IPM, CT
			R6 (2.5)	TET, IPM, AMK, CIP, PIP, GM, CAZ, CT
			R7 (2.5)	TET, IPM, AMK, CIP, PIP, GM, CAZ
			R8 (2.5)	TET, AMK, CIP, PIP, GM, CRO, CT
P4	1.9	7.5	R12 (5)	TET, IPM, AMK, PIP, CRO, CT
			R13 (2.5)	TET, IPM, AMK, CIP, GM, CAZ, CT
P5	1.3, 1.4, 1.7, 1.9	2.5	R3 (2.5)	TET, IPM, AMK, CIP, PIP, GM, CAZ, CRO, CT
P6	1.3, 1.4, 1.9, 20	2.5	R12 (2.5)	TET, IPM, AMK, PIP, CRO, CT
P7	1.3, 1.4, 1.7, 20	15	R3 (7.5)	TET, IPM, AMK, CIP, PIP, GM, CAZ, CRO, CT
			R12 (2.5)	TET, IPM, AMK, PIP, CRO, CT
			R10 (2.5)	TET, IPM, AMK, CIP, PIP, GM, CAZ, CRO
			R6 (2.5)	TET, IPM, AMK, CIP, PIP, GM, CAZ, CT
P8	1.4, 1.20	2.5	R7 (2.5)	TET, IPM, AMK, CIP, PIP, GM, CAZ
P9	20	5	R4 (5)	TET, IPM, AMK, CIP, PIP, GM, CT

\* CRO: ceftriaxone; CT: ceftizoxime; CAZ: ceftazidime; AMK: amikacin; TET: tetracycline; CIP: ciprofloxacin; GM: gentamicin; PIP: piperacillin; IPM: imipenem

Results obtained from E-test showed that 100% of *P. aeruginosa* strains were resistant to ceftoxitin, 97% to cefotetan, 93% to ticarcillin, 89% to ticarcillin/clav, 76% to gentamicin and imipenem, 63% to piperacillin, 49% to tetracycline, and 20% to meropenem.

All isolates harbored at least a single plasmid band. The electrophoretic analysis of plasmid DNAs showed the existence of 1 to 4 DNA bands ranging from 1.3 to larger than of 20 kbp in the strains tested (Figures 1 and 2). The DNA band of 1.4 kbp was evident in 57.5% of the strains. Based on size and number of DNA bands, plasmid analysis of *P. aeruginosa* isolates resulted in 9 different profiles labeled P1-P9. P2 (30%) was the dominant type followed by P3 (22.5%) (Table 1, Figure 1).

## Discussion

We carried out this study in the year 2007 to determine antibiotic susceptibility and plasmid profiles of *P.*

*aeruginosa* strains isolated from burned patients hospitalized at the Motahari Burn Center in Tehran, Iran. All strains showed multiple drug resistance. As shown in table 1, more than 90% of the isolates were resistant to imipenem, amikacin and tetracycline.

When compared to previous studies carried out in Iran, our finding indicated that the rate of resistance against some antibiotics tested has increased in recent years. Previously, resistance to imipenem has been reported 32.9%, 25%, 2.9 and 5.6% in our country in the years 2003 (13), 2005 (14), 2006 (6) and 2007 (15) respectively.

More than 87% of our isolates were found to be resistant to piperacillin while previous resistance rate for this antibiotic was reported 33.7% and 84% by Nikbin *et al.* (6) and Japoni *et al.* (13) respectively. Similarly, lower resistance rates against tetracycline and ceftriaxone were reported among *P. aeruginosa* strains isolated in Iran in the years 2002 (5) and 2006 (6). On the other hand, the resistance rate was relatively constant

## Characterization of *Pseudomonas aeruginosa* strains

for amikacin and ciprofloxacin when compared to previous reports in Iran (5,13,16).

Interestingly our results showed that the percentage of resistance to ceftizoxime (72.7%) and gentamicin (67.5%) was decreased in comparison with previous reports published from our country (5,6,16).

Here we also used antimicrobial drug resistance pattern analysis as an epidemiological marker for our isolates. This method is least expensive and could be considered as a preliminary screening tool in assessing the strain relatedness. This simple method has been widely applied in epidemiologic studies of *P. aeruginosa* through the years (5,17,18). Using this method, 13 resistant phenotypes were recognized suggesting this method may represent a discriminative approach for differentiation of *P. aeruginosa*.

Some previous studies have used plasmid profiles to characterize the isolates of *P. aeruginosa* (5,6,19-25). This method is cheap and quick, requiring one hour approximately of hands-on time, and 24 hours to be completed. The results obtained from electrophoretic analysis of plasmid DNAs showed the presence of plasmid bands in all strains tested. The sizes of the plasmids among *P. aeruginosa* isolates ranged from 1.3 to 20 kb. Nine different plasmid profiles were observed among the strains, P2 was predominant (30%) followed by P3 (22.5%). In a recent study carried out in our country, Nikbin *et al.* identified 15 plasmid patterns among 31 strains of *P. aeruginosa* recovered from clinical and environmental specimens in Tehran, in the year 2006. Those patterns contained 1-7 plasmids which ranged in size from 1.7 to 100 kb (6).

Poh *et al.* found the plasmid profiling was to be a useful method adjunct to serotyping for the epidemiological typing of *P. aeruginosa* (25). This statement was also noted by Wu in a study carried out on 120 clinical strains of *P. aeruginosa* isolated in Nanjing City (22).

Walia and colleagues demonstrated that the combination of plasmid DNA profile or serotyping with electrophoretic patterns of soluble proteins can be of value in the epidemiologic fingerprinting of clinical isolates of *P. aeruginosa* (23).

In another study carried out by Plesiat and colleagues, however this technique appeared to be less appropriate as an epidemiological tool for this organism than other techniques since only 13.9% of the strains tested harbored plasmids and the majority of these plasmids were antibiotic resistant (19).

In this study we found any obvious correlation between plasmid profiles and antibiotic resistance

patterns among *P. aeruginosa* strains. No correlation was also observed between the antibiotic resistance patterns and the kind of specimens in which the isolates were isolated. The results obtained from plasmid profiling indicated that 70% of the strains isolated from burn wounds have shown plasmid pattern 2 however there was any obvious correlation between other profiles and specimens.

The current study showed an increase rate of resistance for some antibiotics tested among *P. aeruginosa* strains isolated from burned patients in Tehran that merits immediate attention. We recommend Iranian health care practitioners and policy makers to address this problem by implementing an appropriate use of antibiotics. A combination of antibiotic susceptibility testing and profile plasmid analysis, which are relatively cheap and available methods in our country, could be useful for epidemiological studies particularly in research laboratories in the developing world with limited resources.

## Acknowledgements

We thank Dr. Malihe Talebi for help to interpret the plasmid profiles.

## References

1. Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. *Clin Microbiol Rev* 2006;19(2):403-34.
2. Pruitt BA Jr, McManus AT, Kim SH, Goodwin CW. Burn wound infections: current status. *World J Surg* 1998;22(2):135-45.
3. Pirnay JP, De Vos D, Cochez C, Bilocq F, Pirson J, Struelens M, Duinslaeger L, Cornelis P, Zizi M, Vanderkelen A. Molecular epidemiology of *Pseudomonas aeruginosa* colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone. *J Clin Microbiol* 2003;41(3):1192-202.
4. Enoch DA, Simpson AJ, Kibbler CC. Predictive value of isolating *Pseudomonas aeruginosa* from aerobic and anaerobic blood culture bottles. *J Med Microbiol* 2004;53(Pt 11):1151-4.
5. Shahcheraghi F, Feizabadi MM, Yamin V, Abiri R, Abedian Z. Serovar determination, drug resistance patterns and plasmid profiles of *Pseudomonas aeruginosa* isolated from burn patients at two hospitals of Tehran (IRAN). *Burns* 2003;29(6):547-51.
6. Nikbin VS, Abdi-Ali A, Feizabadi MM, Gharavi S. Pulsed field gel electrophoresis & plasmid profile of *Pseudomonas aeruginosa* at two hospitals in Tehran, Iran. *Indian J Med Res* 2007;126(2):146-51.

7. Hall GS. Nonfermenting Gram negative bacilli. In: Mahon CR, Manuselis G, editors. *Textbook of Diagnostic Microbiology*. 2<sup>nd</sup> ed. Philadelphia: WB Saunders; 2000. p. 542-62.
8. Forbes BA, Sahm DF, Weissfeld A, editors. *Bailey and Scott's Diagnostic Microbiology*. 11<sup>th</sup> ed. St. St Louis: Mosby Inc; 2002.
9. National Committee for Clinical Laboratory Standards (NCCLS). *Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Information Supplement*. [Online] 2011 Jan [cited 2011 Aug 15]; M100-S12;31(1); Available from: URL:<http://www.clsi.org/source/orders/free/m100-s21.pdf>
10. Ranjbar R, Mammina C, Pourshafie MR, Soltan-Dallal MM. Characterization of endemic *Shigella boydii* strains isolated in Iran by serotyping, antimicrobial resistance, plasmid profile, ribotyping and pulsed-field gel electrophoresis. *BMC Res Notes* 2008;1:74.
11. Ranjbar R, Soltan Dallal MM, Talebi M, Pourshafie MR. Increased isolation and characterization of *Shigella sonnei* obtained from hospitalized children in Tehran, Iran. *J Health Popul Nutr* 2008;26(4):426-30.
12. Ranjbar R, Owlia P, Saderi H, Bameri Z, Izadi M, Jonaidi N, Morovvati S. Isolation of clinical strains of *Pseudomonas aeruginosa* harboring different plasmids. *Pak J Biol Sci* 2007;10(17):3020-2.
13. Japoni A, Farshad S, Alborzi A, Kalani M, Mohamadzadegan R. Comparison of arbitrarily primed-polymerase chain reaction and plasmid profiles typing of *Pseudomonas aeruginosa* strains from burn patients and hospital environment. *Saudi Med J* 2007;28(6):899-903.
14. Hadadi A, Rasoulinejad M, Maleki Z, Yonesian M, Shirani A, Kourorian Z. Antimicrobial resistance pattern of Gram-negative bacilli of nosocomial origin at 2 university hospitals in Iran. *Diagn Microbiol Infect Dis* 2008;60(3):301-5.
15. Boroumand MA, Esfahanifard P, Saadat S, Sheikhvatan M, Hekmatyazdi S, Saremi M, Nazemi L. A report of *Pseudomonas aeruginosa* antibiotic resistance from a multicenter study in Iran. *Indian J Med Microbiol* 2007;25(4):435-6.
16. Rastegar Lari A, Bahrami Honar H, Alaghebandan R. *Pseudomonas* infections in Tohid Burn Center, Iran. *Burns* 1998;24(7):637-41.
17. Ferreira AC, Gobara S, Costa SE, Sauaia N, Mamizuka EM, van der Heijden IM, Soares RE, Almeida GD, Fontana C, Levin AS. Emergence of resistance in *Pseudomonas aeruginosa* and *Acinetobacter* species after the use of antimicrobials for burned patients. *Infect Control Hosp Epidemiol* 2004;25(10):868-72.
18. Igumbor E, Gwanzura L, Chirara M, Obi C, Muza D. Antibiotic sensitivity and plasmid profiles of *Pseudomonas aeruginosa*. *Cent Afr J Med* 2000;46(11):296-300.
19. Plesiat P, Alkhalaf B, Michel-Briand Y. Prevalence and profiles of plasmids in *Pseudomonas aeruginosa*. *Eur J Clin Microbiol Infect Dis* 1988;7(2):261-4.
20. Puzová H, Siegfried L, Kmetová M, Durovicová J, Kerestesová A. Characteristics of *Pseudomonas aeruginosa* strains isolated from urinary tract infections. *Folia Microbiol (Praha)* 1994;39(4):337-41.
21. Mascellino MT, Iegri F, Delogu G, Catania S, Sorice F. Plasmid profile as epidemiological marker for *Pseudomonas aeruginosa* in an intensive care unit. *J Chemother* 1989;1(4 Suppl):401-3.
22. Wu T. Plasmid profiles of 120 strains of *Pseudomonas aeruginosa*. *Zhonghua Liu Xing Bing Xue Za Zhi* 1993;14(5):304-6.
23. Walia S, Madhavan T, Williamson T, Kaiser A, Tewari R. Protein patterns, serotyping and plasmid DNA profiles in the epidemiologic fingerprinting of *Pseudomonas aeruginosa*. *Eur J Clin Microbiol Infect Dis* 1988;7(2):248-55.
24. Ding MJ, Wu TM. Serogrouping, plasmid and drug resistance of *Pseudomonas aeruginosa* in Taiwan. *Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi* 1988;21(3):165-78.
25. Poh CL, Yap EH, Tay L, Bergan T. Plasmid profiles compared with serotyping and pyocin typing for epidemiological surveillance of *Pseudomonas aeruginosa*. *J Med Microbiol* 1988;25(2):109-14.